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Comparative Investigation on the Activity of a Synthetic Corticotrophin (18-ACTH)
A Clinical Trial
By P. J. Brombacher, Department of Clinical Chemistry
F. P. V. Maesen, Department ofPneumology
and A. H. J. Gijzen, Department of Clinical Chemistry
The DeWever-Ziekenhuis, Heerlen (L), The Netherlands
(Eingegangen am 7. Februar/11. April 1974)
The effect of the administration of a synthetic peptide with corticotrophic properties (18-ACTH) on the plasma corticosteroid levels
of 72 healthy volunteers was studied. The same effect is seen both after subcutaneous and intramuscular injection. Intravenous admi-
nistration provokes a longer lasting influence on adrenocortical activity, especially when large doses of the peptide are given; side
effects however plead against this method of stimulation of the adrenal cortex.
Discrepancies are reported between results from the fluorometric and radioimmuno assay of corticosteroids.
An 72 gesunden Probanden wurde der Einfluß der Applikation eines synthetischen Peptids mit Gorticotropin-Eigenschaften (18-ACTH)
auf die Corticosteroid-Konzentration im Plasma untersucht. Nach s.c.- und i.v.-Injektion wurde dieselbe Wirkung beobachtet. I.v.-
Applikation bedingt eine länger dauernde Wirkung auf die Nebennieren-Aktivität, besonders nach Gabe hoher Dosen des Peptids.
Wegen der Nebenwirkungen ist diese Art der Stimulation jedoch nicht zu empfehlen.
Fluorimetrische Bestimmung der Corticosteroide und Radioimmunoassay ergaben unterschiedliche Werte.
The favourable effect of long term treatment of many
diseases by corticosteroids is now generally recogni-
zed. An unwanted side effect of this therapy however is
the continuous inhibition of the production of adreno-
corticotrophin by the patient's hypophysis; this can
eventually lead to hypotrophy or even atrophy of the
adrenal cortex. In order to prevent this, corticosteroid
therapy is often accompanied by parenteral admini-
stration of corticotrophin at regular intervals. In a
number of cases (about 5 %) allergy was raised either
against the animal (porcine) corticotrophin used or
against accompanying protein impurities (1,2, 3). Oil
account of this serious complication the risk of allergy
had always to be balanced against the risk of adrenal cor-
tex functional loss.
The situation was considerably improved when synthetic
polypeptides with corticotrophic activity became avai-
lable (4, 5), which can be regarded as far safer for use
in human medicine; first because it is less likely that
large molecules of foreign protein could be present as
impurities arid secondly because there is no difference
in the sequence of the first 24 amino acids of ACTH in
man and some animals (6,7).
This synthetic ß1""24-corticotrophin appears to have
acceptable corticotrophic activity although stimu-
lation of the adrenal cortex is less than with ACTH of
animal origin. Therapeutic use is now generally accep-
ted (8).
In order to overcome the drawback of reduced acti-
vity, however, the synthesis of peptides with cortico-
trophic activity which are less biodegradable due to
minor changes in the amino acid chain was investi-
gated. These peptides should be long acting without
the usual additives like zinc phosphate in the so called
depot preparations (9,10). An example is D-serine-
L-dilysine-17, IS-jS^^-corticotropinamide which we
obtained for the clinical trial1) described here.
The effect of the administration of this substance to
volunteers is reported in terms of plasma corticosteroid
levels determined in two ways (11,12).
Purpose of the investigation
With regard to experiments in animals (13) and reports
on the clinical use of this so called 18-ACTH in a
small number of patients (14) it can be expected that
the substance will have good corticotrophic activity
and will be long acting when administered to man.
A systematic investigation is performed with the help
of 72 healthy volunteers. The mean body weight of
the probands was 61.7 kg, standard deviation 9.9 kg.
*) Courtesy of CIBA-GEIGY Ltd.
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Their ages ranged from 18 to 46 years. No distinction
was made between males and females. Neither of them
took any drugs shortly before or during the trial.
Twelve blocks are formed by randomization. Six per-
sons in one group all received the same treatment. The
drug was administered either by subcutaneous injection
or by intravenous injection or by intramuscular injec-
tion. The solvent used for the corticotrophins was
0.9 % sodium chloride solution in water. The doses of
0.125 mg, 0.25 mg and 0.5 mg were administered in
0.5 ml solvent; the 1.0 mg doses were administered in
1.0 ml of solvent; those volumes were used for subcu-
taneous and intramuscular injections. Intravenous in-
jections were given in 5 ml of solvent slowly admini-
stered during two minutes in order to avoid unwanted
reactions towards the injected peptide.
In each mode of administration four different doses
were used (0.125 mg, 0.25 mg, 0.50 mg and 1.00 mg)
to determine, if possible, the most suitable dose and
method to obtain optimal stimulation of the human
adrenal cortex\when using the new drug.
Materials and Methods
The volunteers were hospitalized on the evening preceding
the onset of the experiment. During the course of the trial
they were strictly confined to their beds; no stress or
smoking was allowed. The next morning a blood sample was
taken at 8 a.m. whereupon the 18-ACTH was administered.
More blood samples were taken after 2, 4, 8,12, 24, and
after intravenous administration also after 36 and 48 hours.
The heparinised blood samples were taken to the laboratory
at once where plasma was separated by centrifugation and
frozen immediately in small portions at - 20° C. Analysis
was always performed within three days.
The corticotrophic effect of the administered preparation
was measured on plasma corticosteroid levels. The amount
of corticosteroids in each plasma sample was determined
in two ways:
i) by measuring the fluorescence of the dichloromethane
extract of plasma in ethanol/sulfuric acid according to
the method described by Mattingly (11); excitation light
433 nm and emission wave length 539 nm. Cortisol was used
as a standard.
ii) by radioimmunoassay of the corticosteroids extracted
from plasma by means of dichloromethane, using a described
procedure (12) with the modification that instead of tritiated
cortisol as a tracer we used cortisolsuccinylr125I-tyrosine
methylester as a tracer on account of its ^-radiation. Again
cortisol was taken as the standard.
In a number of samples total plasma ACTH was estimated in
order to investigate possible correlation between values
found for ACTH and plasma corticosteroids.
The estimation of ACTH was performed by radioimmuno-
assay (16) after extraction of corticotrophins from the plasma
by means of porous glass beads (17). With the commercially
available antibody (Radiochemical Centre, Amersham, Bucks.,
Great Britain) we used there was 90 % cross reactivity
towards purified human ACTH and 18-ACTH (to be publi-
shed). The values found have thus to be regarded as represen-
ting the total amounts of endogenous and administered
corticotrophins. Human ACTH (fraction 8B - Lerner and
Upton) was used as a standard.
Results '
Table 1 gives the results of corticosteroid analyses.
(Standard deviations of the mean values are indicated
at the bottom of the table.) Most elevated values are
found after administration of the largest dose of
18-ACTH. As might be expected the fluorometric
analysis gives values which are more elevated than
those obtained by radioimnninoassay. There seems to
be no appreciable difference between the effects of
0.25 mg and 0.50 mg of 18-ACTH. It should be con-
sidered however that the corticotrophic effect cannot
be fully evaluated by the maximal plasma cortisol
level obtained. The duration of the stimulation should
be taken into account äs well. Therefore the overall
effect is better measured by calculating the surface
under the curve in the graphical presentation of plasma
cörticisteroid values versus time. Those calculated
values are given in table 2. Once more there appears to
be not much difference between the effects of 0.25 mg
and 0.50 mg of 18-ACTH. There are no striking diffe-
rences between the effects of subcutaneous or intra-
muscular administration, which is in accordance with
pur own previous experience with other corticotrophic.
peptides (15). It is quite clear, however, that intravenous
administration of the drug has a more pronounced
effect.
It should also be noted that maximal stimulation of
the adrenal cortex is readily effected also after admini-
stration of rather small doses of 18-ACTH. The effect
of larger doses is seen largely on the duration of stimu-
lation (fig. 1).
18-ACTH [mg]
0,5-
Fig. 1. Plasma corticosteroid levels after intramuscular administra-
tion of different doses of 18-ACTH.
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Tab. 1. Plasma corticosteroid levels after administration of 18-ACTH
Dose of Mode of
18-ACTH admhii-
(mg) stration
0.125 s.c.
i.m.
i.v.
0.25 s.c.
i.m.
i.v.
0.50 s.c.
i.m.
i.v.
1.00 s.c.
i.m.
i.v.
Corticosteroid levels (μηιοΐ/ΐ) after
O h 2 h 4 h
0.57
0.75
0.70
0.76
0.80
0.79
0.57
0.24
0.77
0.77
0.69
0.20
0.52
0.79
0.72
0.18
0.70
0.22
0.64
0.79
0.66
0.23
0.70
0.23
1.14
0.42
1.17
0.34
1.32
0.25
1.16
0.47
1.33
0.42
1.38
0.26
1.07
0.45
1.26
0.35
1.45
0.29
1.18
0.47
1.26
0.39
1.45
0.32
0.92
0.53
1.08
0.43
1.54
0.32
1.27
0.55
1.48
0.49
1.66
0.37
1.27
0.48
1.41
0.53
1.69
0.34
1.40
0.50
1.49
0.46
1.70
0.42
8h
0,39
0.55
0.54
0.33
1.30
0.39
1.03
0.52
1.11
0.37
1.78
0.42
1.23
0.56
1.20
0.37
1.77
0.43
1.40
0.52
1.62
0.32
1.94
0.47
12h
0.27
0.40
0.34
0.23
0.97
0.35
0.62
0.37
0.69
0.24
1.67
0.37
0.91
0.44
0.86
0.22
1.72
0.34
1.15
0.37
1.47
0.27
2.05
0.40
24 h 36 h
0.60
0.18
0.62
0.77
0.52 0.40
0.37 0.24
0.49
0.79
0.58
0.77
0.99 0.42
0.30 0.26
0.52
0.20
0.54
0.18
1.26 0.54
0.29 0.23
0.54
0.79
0.79
0.77
1.95 1.17
0.33 0.27
48h
0.70
0.79
0.61
0.23
0.63
0.25
0.77
0.25
Corticosteroid values were estimated by fluorometric analysis (f) and by radio-immuno-assay (ria). Each value given is the mean of six
independent values. Standard deviations of the means (SEM) are s-% = 0.16 (f) and s^ = 0.04 (ria).
Tab. 2. Relative activity of different doses of 18-ACTH expressed
as surface (cm2) under the curves in the graphical presen-
tation of plasma-corticosteroid levels against time after
administration. Calculated values from fluorometric and
from radiO'immuno-assay methods for corticosteroid esti-
mation.
Variation coefficient for fluorimetric assay 10 % and for
radioimmunoassay 9 %.
Administration Doseofl8-ACTH(mg)
0.125 0.25
Surface (cm2)
0.50 1.00
subcutaneous
intramuscular
intravenous
128.6
90.7
147.8
63. 6
240.3
78.8
187.9
92.0
211.5
70.4
341.1
86.2
214.8
94.8
222.5
67.4
370.2
79.7
252.0
57.3
304.8
63.2
443.6
92.0
In tables 3 a and 3b measured plasma ACTH values are
given. These values are composed of the sum of ad-
ministered j31~18-corticotrophinamide and endogenous
human ACTH. Relatively elevated values are detected
very soon after the subcutaneous or intravenous admini-
stration of the synthetic drug. In the latter case ho-
wever the values diminish more rapidly, possibly on
account of suppression of endogenpus ACTH produc-
tion by rapidly increasing plasma cortisol values as a
result of the action of the administered 18-ACTH on
the adrenal cortex.
Conclusions
a. After administration of 18-ACTH in doses ranging
from 0.125 mg to 1.00 mg there is not much difference
in the attained plasma corticosteroid levels. The observed
effect of the drug on adrenocortical activity is more
persistent after the administration of the larger doses.
b. About the same corticotrophic activity is obtained
after administration of either 0.25 mg or 0.50 mg of
18-ACTH. It therefore seems unnecessary to use the
larger dose.
c. Intravenous administration of the drug has the
stronger effect for all doses. However it should be
mentioned here that in some cases after the administra-
tion of 1.00 mg of 18-ACTH by intravenous injection,
significant weight gain (up to 3 kg) was observed which
might be due to water retention; this lasted for up to
four days. In some cases, this same intravenous dose
also caused generalized erythema, which developed
within a few minutes after the injection and disappeared
again within fifteen minutes. As the participants in the
trial had not been sensitized before, this erythema
can not be considered as a specific allergic reaction.
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Tab. 3 a. Total content of corticotrophins in plasma after admini-
stration of 0.25 mg of 18-ACTH via different modes of
administration:
corticotrophins estimated by radio-immuno-assay,
Variation coefficient 16%.
Mode of Time after administration (hours)
admini- 0 2 4 8 12 24 36 48
stration Total corticotrophins (/ug/1)
subcuta-
neous 83 175 338 342 195 90
intramus-
cular 89 174 194 345 269 129
intra-
venous 89 193 366 226 271 125 133 85
Tab. 3b. Total content of corticotrophins in plasma after admini-
stration of 18-ACTH.
Variation coefficient 16 %.
Dose of
18-ACTH
(mg)
0.125
0.25
0.25
0.25
1.00
Admini- Time after administration (hours)
stration 0 2 4 8 12 24 36
Total .corticotrophin Gig/1)
s.c. 92
s.c. 83
i.m. 89
i.v. 89
i.v. 83
163
175
174
193
374
222
338
194
366
374
2 4>
342
345
226
274
163
195
269
271
220
96
90
129
125 133
200 125
48
85
108
On account of these side effects we do not recommend
the use of the drug for intravenous administration,
d. The corticosteroid values as estimated by radio-immu-
noassay are significantly lower than those obtained by
fluorometric analysis. This is probably due to greater
selectivity of the immunological procedure. The que-
stion arises whether it would be advisable to abandon
the fluorometric method in investigations as described
here. This depends on the problem of the better para-
meter of adrenocortical activity: plasma cortisol values
or total plasma corticosteroid values. For the time
being we think the overall fluorometric method should
be retained.
e. There is no evident relation between the measured
values of total plasma corticotrophins and the cortico-
steroid values obtained by either method. This might
be due to lack of specificity of the corticotrophin esti-
mation where both the administered and the endoge-
nous peptides are measured simultaneously.
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